Invivyd to Participate at Cowen’s 43rd Annual Healthcare Conference
On February 28, 2023, Invivyd, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IVVD, announced that CEO David Hering will present at Cowen's 43rd Annual Healthcare Conference on March 6, 2023, at 2:10 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On February 28, 2023, Invivyd, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker IVVD, announced that CEO David Hering will present at Cowen's 43rd Annual Healthcare Conference on March 6, 2023, at 2:10 p.m. ET. The presentation will be available as a live webcast and archived for 90 days on the company’s investor website. Invivyd focuses on combating viral respiratory diseases through innovative antibody development, particularly targeting COVID-19. The company aims to enhance natural immunity to provide superior viral protection.
Details
News Market Reaction – IVVD
The recorded move for IVVD in the trading session of this news was -0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen’s 43rd Annual Healthcare Conference on Monday, March 6, 2023 at 2:10 p.m. ET.
A live webcast of the presentation will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation.
About Invivyd
(Nasdaq: IVVD)
Invivyd, Inc., formerly Adagio Therapeutics (Nasdaq: ADGI), is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. Visit www.invivyd.com to learn more.
Media Contact:
Kate Burdick, Evoke Canale
860-462-1569
kate.burdick@evokegroup.com
Investor Contact:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.